Boosting capacity of a fourth dose BNT162b2 in cancer patients
Source
European journal of cancer - ISSN 0959-8049-179 (2023) p. 121-123
Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in patients with cancer
Source
Clinical cancer research - ISSN 1078-0432-29:3 (2023) p. 635-646
Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors
Source
Frontiers in immunology - ISSN 1664-3224-13 (2022) p. 1-10
Comparison of S1 antibody titers between BNT162b2 and ChAdOx1 COVID-19 vaccination in cancer patients
Source
ESMO Open - ISSN 2059-7029-7:2 (2022) p. 1-2
Antibody titers before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in cancer patients
Source
European journal of cancer - ISSN 0959-8049-163 (2022) p. 177-179